Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study

被引：0
|
作者：
Peng, Peijian
Xu, Xiaolu
Zhong, Jincai
Ye, Jin-Hui
Wang, Zhi-Hui
Wang, Hong
Lin, Hong
Du, Caiwen
Zou, Guorong
Ouyang, Jie
Shi, Ying-ying
Xu, Fei
Yu, Gengsheng
Lu, Yongkui
Wang, Yong-Xia
Cui, Shi-En
Li, Lu-Zhen
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Dept Breast Dis, Zhuhai, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] First Peoples Hosp Zhaoqing, Dept Breast Oncol, Zhaoqing, Peoples R China
[4] Jiangmen Cent Hosp, Jiangmen, Peoples R China
[5] Zhuhai Matern & Child Hlth Hosp, Dept Breast Surg, Zhuhai, Guangdong, Peoples R China
[6] Zhuhai Hosp Integrated Tradit Chinese & Western M, Dept Breast Dis, Zhuhai, Guangdong, Peoples R China
[7] Chinese Acad Med Sci, Canc Hosp, Shenzhen Ctr, Shenzhen, Peoples R China
[8] Panyu Cent Hosp, Guangzhou, Peoples R China
[9] Dongguan Peoples Hosp 3, Dongguan, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China
[11] State Key Lab Oncol South China, Guangzhou, Peoples R China
[12] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[13] Guangxi Med Univ Canc Ctr, Guangxi, Peoples R China
[14] Dongguan Peoples Hosp, Dongguan, Peoples R China
[15] Zhongshan City Peoples Hosp, Dept Gen Surg, Breast Ctr, Zhongshan, Peoples R China
[16] Guangzhou Univ Tradit Chinese Med, Zhongshan Hosp Tradit Chinese Med, Zhongshan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13139
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
    Ortega, Vanesa
    Anton, Antonio
    Garau, Isabel
    Afonso, Nomia
    Calvo, Lourdes
    Fernandez, Yolanda
    Martinez-Garcia, Maria
    Blanco, Esperanza
    Zamora, Pilar
    Garcia, Mirta
    Juan Illarramendi, Jose
    Rodriguez Sanchez, Csar Augusto
    Sampayo, Miguel
    Aguirre, Elena
    Manuel Perez-Garcia, Jose
    Cortes, Javier
    Llombart-Cussac, Antonio
    CLINICAL BREAST CANCER, 2019, 19 (02) : 105 - 112
  • [22] Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: A multicenter, open-label, single-arm phase II study
    Srimuninnimit, Vichien
    Sriuranpong, Virote
    Suwanvecho, Suthida
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 255 - 260
  • [23] Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
    Zhang, Yan
    Xu, Junying
    Wang, Qiong
    Ling, Guohong
    Mao, Yong
    Cai, Maohuai
    Yang, Yang
    Mei, Jingfeng
    Han, Zhengxiang
    Feng, Jifeng
    Wu, Yuan
    Shi, Lin
    Wen, Shaodi
    Shen, Bo
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (11)
  • [24] Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
    Pernas, Sonia
    Martin, Miguel
    Kaufman, Peter A.
    Gil-Martin, Marta
    Gomez Pardo, Patricia
    Lopez-Tarruella, Sara
    Manso, Luis
    Ciruelos, Eva
    Alejandro Perez-Fidalgo, Jose
    Hernando, Cristina
    Ademuyiwa, Foluso O.
    Weilbaecher, Katherine
    Mayer, Ingrid
    Pluard, Timothy J.
    Martinez Garcia, Maria
    Vahdat, Linda
    Perez-Garcia, Jose
    Wach, Achim
    Barker, Debra
    Fung, Samson
    Romagnoli, Barbara
    Cortes, Javier
    LANCET ONCOLOGY, 2018, 19 (06): : 812 - 824
  • [25] Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
    Ni, M.
    Zhou, L.
    Lu, Y.
    Zhang, L.
    Li, X.
    Chen, M.
    Yang, A.
    Zhang, L.
    Xu, F.
    Yuan, Z.
    Wang, S.
    Shi, Y.
    An, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1490 - S1490
  • [26] Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
    Michael R. Clemens
    Oleg A. Gladkov
    Elaina Gartner
    Vladimir Vladimirov
    John Crown
    Joyce Steinberg
    Fei Jie
    Anne Keating
    Breast Cancer Research and Treatment, 2015, 149 : 171 - 179
  • [27] Phase II, multicenter, open-label, randomized study of YM155 plus docetaxel as first-line treatment in patients with HER2-negative metastatic breast cancer
    Clemens, Michael R.
    Gladkov, Oleg A.
    Gartner, Elaina
    Vladimirov, Vladimir
    Crown, John
    Steinberg, Joyce
    Jie, Fei
    Keating, Anne
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 171 - 179
  • [28] A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
    Wuelfing, Christian
    Machiels, Jean-Pascal H.
    Richel, Dirk J.
    Grimm, Marc-Oliver
    Treiber, Uwe
    De Groot, Marco R.
    Beuzeboc, Philippe
    Parikh, Roma
    Petavy, Frank
    El-Hariry, Iman A.
    CANCER, 2009, 115 (13) : 2881 - 2890
  • [29] Gemcitabine plus Nab-paclitaxel as a second-line treatment for patients with advanced pancreatic cancer after FOLFIRINOX failure: a multicenter, single-arm, open-label, phase 2 trial
    Choi, Jin Ho
    Lee, Hee Seung
    Huh, Gunn
    Lee, Sang Hyub
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Bang, Seungmin
    Lee, Eaum Seok
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 122 - 122
  • [30] Gemcitabine plus nab-paclitaxel for second-line therapy of pancreatic cancer: A phase II, single-arm, multicenter study
    Huh, Gunn
    Choi, Jin Ho
    Lee, Sang Hyub
    Chun, Jung Won
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    Lee, Hee Seung
    Bang, Seungmin
    ANNALS OF ONCOLOGY, 2021, 32 : S287 - S287
12345